Artificial Oxygen Carrier as Therapeutics Rather Than Blood Substitute for Transfusion

Kawaguchi, Akira T.

doi:10.1111/aor.12917

Cited by 6 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infusing extracellular hemoglobin (Hb) into the vasculature has clinical potential as a blood substitute, 1 oxygen carrying therapeutic 2 or drug delivery agent. 3 However, native hemoglobin is in rapid equilibrium between tetrameric (≈64 kDa) and dimeric (≈32 kDa) forms.…”

Section: Introductionmentioning

confidence: 99%

Engineering hemoglobin to enable homogenous PEGylation without modifying protein functionality

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Engineering hemoglobin to enable homogenous PEGylation without modifying protein functionality

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In these cases, the products are acting not as providers of oxygen, but as facilitators of oxygen transferred from the red cells to the hypoxic tissue. These so-called ‘oxygen therapeutics’ have been suggested to be of benefit in a variety of pathologies such as trauma, sickle cell disease, and subarachnoid hemorrhage [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Comparison of the oxidative reactivity of recombinant fetal and adult human hemoglobin: implications for the design of hemoglobin-based oxygen carriers

et al. 2018

View full text Add to dashboard Cite

Hemoglobin (Hb)-based oxygen carriers (HBOCs) have been engineered to replace or augment the oxygen carrying capacity of erythrocytes. However, clinical results have generally been disappointing, in part due to the intrinsic oxidative toxicity of Hb. The most common HBOC starting material is adult human or bovine Hb. However, it has been suggested that fetal Hb may offer advantages due to decreased oxidative reactivity. Large-scale manufacturing of HBOC will likely and ultimately require recombinant sources of human proteins. We, therefore, directly compared the functional properties and oxidative reactivity of recombinant fetal (rHbF) and recombinant adult (rHbA) Hb. rHbA and rHbF produced similar yields of purified functional protein. No differences were seen in the two proteins in: autoxidation rate; the rate of hydrogen peroxide reaction; NO scavenging dioxygenase activity; and the NO producing nitrite reductase activity. The rHbF protein was: less damaged by low levels of hydrogen peroxide; less damaging when added to human umbilical vein endothelial cells (HUVEC) in the ferric form; and had a slower rate of intrinsic heme loss. The rHbA protein was: more readily reducible by plasma antioxidants such as ascorbate in both the reactive ferryl and ferric states; less readily damaged by lipid peroxides; and less damaging to phosphatidylcholine liposomes. In conclusion in terms of oxidative reactivity, there are advantages and disadvantages to the use of rHbA or rHbF as the basis for an effective HBOC.

show abstract

“…More recently there has been interest in the development of “oxygen therapeutics”, Hb solutions designed not to replace blood, but to act in synergy with erythrocytes to deliver oxygen to tissues difficult for red blood cells Hb to access ( Bettati and Mozzarelli, 2011 ). Such oxygen therapeutics have been suggested to play a critical role in new therapeutic interventions in, for example, stroke, trauma and sickle cell disease ( Kawaguchi, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

Stability of Maleimide-PEG and Mono-Sulfone-PEG Conjugation to a Novel Engineered Cysteine in the Human Hemoglobin Alpha Subunit

et al. 2021

View full text Add to dashboard Cite

In order to use a Hemoglobin Based Oxygen Carrier as an oxygen therapeutic or blood substitute, it is necessary to increase the size of the hemoglobin molecule to prevent rapid renal clearance. A common method uses maleimide PEGylation of sulfhydryls created by the reaction of 2-iminothiolane at surface lysines. However, this creates highly heterogenous mixtures of molecules. We recently engineered a hemoglobin with a single novel, reactive cysteine residue on the surface of the alpha subunit creating a single PEGylation site (βCys93Ala/αAla19Cys). This enabled homogenous PEGylation by maleimide-PEG with >80% efficiency and no discernible effect on protein function. However, maleimide-PEG adducts are subject to deconjugation via retro-Michael reactions and cross-conjugation to endogenous thiol species in vivo. We therefore compared our maleimide-PEG adduct with one created using a mono-sulfone-PEG less susceptible to deconjugation. Mono-sulfone-PEG underwent reaction at αAla19Cys hemoglobin with > 80% efficiency, although some side reactions were observed at higher PEG:hemoglobin ratios; the adduct bound oxygen with similar affinity and cooperativity as wild type hemoglobin. When directly compared to maleimide-PEG, the mono-sulfone-PEG adduct was significantly more stable when incubated at 37°C for seven days in the presence of 1 mM reduced glutathione. Hemoglobin treated with mono-sulfone-PEG retained > 90% of its conjugation, whereas for maleimide-PEG < 70% of the maleimide-PEG conjugate remained intact. Although maleimide-PEGylation is certainly stable enough for acute therapeutic use as an oxygen therapeutic, for pharmaceuticals intended for longer vascular retention (weeks-months), reagents such as mono-sulfone-PEG may be more appropriate.

show abstract

Artificial Oxygen Carrier as Therapeutics Rather Than Blood Substitute for Transfusion

Cited by 6 publications

References 24 publications

Engineering hemoglobin to enable homogenous PEGylation without modifying protein functionality

Engineering hemoglobin to enable homogenous PEGylation without modifying protein functionality

Comparison of the oxidative reactivity of recombinant fetal and adult human hemoglobin: implications for the design of hemoglobin-based oxygen carriers

Stability of Maleimide-PEG and Mono-Sulfone-PEG Conjugation to a Novel Engineered Cysteine in the Human Hemoglobin Alpha Subunit

Contact Info

Product

Resources

About